Plasma Therapy Market is expected to reach US$ 1,097.64 million by 2030

According to our new research study on “Plasma Therapy Market Size and Forecast to 2030 – Global and Regional Analysis – by Type, Source, Application, and End User,” the plasma therapy market is expected to grow from US$ 390.25 million in 2022 to US$ 1,097.64 million by 2030; the market is estimated to register a CAGR of 13.80% from 2022 to 2030. Key factors driving the market growth include the rising cases of orthopedic disorders in people, especially in the geriatric population, the rising number of joint and muscle injuries in athletes, and the surging demand for minimally invasive cosmetic procedures. Further, strategic developments through acquisitions and partnerships by companies are creating opportunities in the plasma therapy market.

Platelet-rich plasma (PRP) is a form of regenerative medicine that amplifies natural growth factors in blood to heal tissue. It entails the utilization of the blood plasma obtained from individuals who have successfully recovered from an illness to address the range of medical conditions and foster the process of healing. PRP treatments find applications in orthopedics for the treatment of joint injuries, dermatology in skin rejuvenation procedures, and dentistry for tissue repair.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00004429

The geographic analysis of the plasma therapy market encompasses major regions such as North America, Europe, Asia Pacific, the Middle East & Africa, and South & and Central America. North America dominated the overall market in 2022. The market in North America is segmented into the US, Canada, and Mexico. The US holds the largest market share of the plasma therapy market in the world and North America. Market growth in the country is attributed to the burgeoning adoption of PRP in orthopedic and cosmetic surgeries, rising investments in the healthcare sector, dynamics of the research and development landscape, and USFDA approval for selected PRP therapies.

The plasma therapy market is segmented on the basis of type, source, application, end product, and end user. In terms of type, the market is segmented into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich fibrin. The leukocyte-rich PRP segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Leukocyte-rich PRP (LR-PRP) is a type of PRP that has a higher concentration of neutrophils (white blood cells) than the baseline level. It is generally associated with proinflammatory effects. However, in some cases, LR-PRP can be beneficial to stimulate inflammation in the body to indicate a chronic condition such as tendinopathy.

The plasma therapy market, by source, is bifurcated into autologous and allogeneic. The autologous segment dominated the market in 2022, and the allogeneic segment is anticipated to record a higher CAGR during 2022–2030. Autologous PRP injection is a secure and reliable biological technique that is used for the treatment of different musculoskeletal disorders. PRP injection can effectively support the primary treatment of patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis by suppressing the production of inflammatory cytokines and promoting the growth of synovial fibroblasts.

The plasma therapy market, by application, is segmented into orthopedic conditions, dermatology, dental issues, and others. The dermatology segment held the largest market share in 2022.

In terms of end user, the plasma therapy market is categorized as hospitals and clinics, research institutes, ambulatory surgical centers (ASCs), and others. The hospital and clinics segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market from 2022 to 2030.

Plasma Therapy Market: Competitive Landscape and Key Developments

Major players in the plasma therapy market include B Braun SE; DePuy Synthes Inc.; Medtronic Plc; Siemens Healthineers AG; Stryker Corp.; ZimmerBiomet Holdings Inc.; Brainlab AG; CASCINATION; HEMOSTASIS, LLC; Corin Group; and GE HealthCare Technologies Inc. These leading players adopt strategies such as the launch of new products, expansion and diversification of market presence, and expansion of new customer base, in turn tapping prevailing business opportunities.

A few of the inorganic strategies opted for by players in the plasma therapy market are mentioned below:

• In March 2023, BioLife Plasma Services announced the opening of its plasma donation centers in the United States (US) with new locations in West Springfield, Mass., and Pearland, Texas. This expansion helped the company grow its business network.
• In February 2020, EmCyte, a leading company in platelet-rich plasma and progenitor stem cell biologics, acquired all assets of Cellmedix Holdings LLC, including the Centrepid Platelet Concentrator system. This acquisition enhanced the intellectual property portfolio of EmCyte Corporation and expanded its product development capabilities.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com